LEVERKUSEN, Germany, Sept. 9 [Category: BizPharmaceuticals] -- Bayer Group, a pharmaceutical and life sciences company, posted the following news release:

* * *

Bayer initiates Phase II study of investigational GIRK4 inhibitor in patients with atrial fibrillation

*

Berlin, September 9, 2026 - Bayer announced today the initiation of a global Phase II clinical trial (NCT07625215) evaluating BAY 3670549, an investigational highly selective G-prote . . .

Click here for more information about our products